PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
APLS vs. VRTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between APLS and VRTX is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

APLS vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Apellis Pharmaceuticals, Inc. (APLS) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

50.00%100.00%150.00%200.00%250.00%NovemberDecember2025FebruaryMarchApril
37.78%
234.64%
APLS
VRTX

Key characteristics

Sharpe Ratio

APLS:

-1.18

VRTX:

0.93

Sortino Ratio

APLS:

-2.03

VRTX:

1.29

Omega Ratio

APLS:

0.75

VRTX:

1.19

Calmar Ratio

APLS:

-0.82

VRTX:

1.03

Martin Ratio

APLS:

-1.74

VRTX:

2.80

Ulcer Index

APLS:

37.54%

VRTX:

8.52%

Daily Std Dev

APLS:

55.10%

VRTX:

25.79%

Max Drawdown

APLS:

-79.96%

VRTX:

-91.77%

Current Drawdown

APLS:

-79.28%

VRTX:

-4.05%

Fundamentals

Market Cap

APLS:

$2.44B

VRTX:

$124.48B

EPS

APLS:

-$1.60

VRTX:

-$2.08

Total Revenue (TTM)

APLS:

$609.04M

VRTX:

$8.32B

Gross Profit (TTM)

APLS:

$511.08M

VRTX:

$7.13B

EBITDA (TTM)

APLS:

-$95.68M

VRTX:

-$856.70M

Returns By Period

In the year-to-date period, APLS achieves a -39.42% return, which is significantly lower than VRTX's 23.13% return.


APLS

YTD

-39.42%

1M

-21.61%

6M

-29.40%

1Y

-62.68%

5Y*

-9.61%

10Y*

N/A

VRTX

YTD

23.13%

1M

-1.77%

6M

2.27%

1Y

25.04%

5Y*

14.25%

10Y*

14.82%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

APLS vs. VRTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APLS
The Risk-Adjusted Performance Rank of APLS is 55
Overall Rank
The Sharpe Ratio Rank of APLS is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of APLS is 33
Sortino Ratio Rank
The Omega Ratio Rank of APLS is 55
Omega Ratio Rank
The Calmar Ratio Rank of APLS is 66
Calmar Ratio Rank
The Martin Ratio Rank of APLS is 77
Martin Ratio Rank

VRTX
The Risk-Adjusted Performance Rank of VRTX is 8383
Overall Rank
The Sharpe Ratio Rank of VRTX is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of VRTX is 7878
Sortino Ratio Rank
The Omega Ratio Rank of VRTX is 7979
Omega Ratio Rank
The Calmar Ratio Rank of VRTX is 8888
Calmar Ratio Rank
The Martin Ratio Rank of VRTX is 8282
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

APLS vs. VRTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for APLS, currently valued at -1.18, compared to the broader market-2.00-1.000.001.002.00
APLS: -1.18
VRTX: 0.93
The chart of Sortino ratio for APLS, currently valued at -2.03, compared to the broader market-6.00-4.00-2.000.002.004.00
APLS: -2.03
VRTX: 1.29
The chart of Omega ratio for APLS, currently valued at 0.75, compared to the broader market0.501.001.502.00
APLS: 0.75
VRTX: 1.19
The chart of Calmar ratio for APLS, currently valued at -0.82, compared to the broader market0.001.002.003.004.00
APLS: -0.82
VRTX: 1.03
The chart of Martin ratio for APLS, currently valued at -1.74, compared to the broader market-5.000.005.0010.0015.0020.00
APLS: -1.74
VRTX: 2.80

The current APLS Sharpe Ratio is -1.18, which is lower than the VRTX Sharpe Ratio of 0.93. The chart below compares the historical Sharpe Ratios of APLS and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.50NovemberDecember2025FebruaryMarchApril
-1.18
0.93
APLS
VRTX

Dividends

APLS vs. VRTX - Dividend Comparison

Neither APLS nor VRTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

APLS vs. VRTX - Drawdown Comparison

The maximum APLS drawdown since its inception was -79.96%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for APLS and VRTX. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-79.28%
-4.05%
APLS
VRTX

Volatility

APLS vs. VRTX - Volatility Comparison

Apellis Pharmaceuticals, Inc. (APLS) has a higher volatility of 19.43% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 6.27%. This indicates that APLS's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%NovemberDecember2025FebruaryMarchApril
19.43%
6.27%
APLS
VRTX

Financials

APLS vs. VRTX - Financials Comparison

This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab